Author: acn

香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 今日，市场关注到首程控股（00697.HK）股价出现一定波动，叠加个别股份变动安排，引发部分投资者讨论。综合公司近期公告、公开行情数据及市场结构变化情况来看，相关波动更多体现为阶段性资金博弈。在资本结构持续优化、产业主线逻辑清晰的背景下，公司基本面未发生实质性变化。市场人士透露，在近期市场调整过程中，部分国际长线资金通过协议及大宗方式完成战略性布局，实现了筹码结构的有序转换。相关观点认为，这种"短期筹码向长期资本转移"的过程，有助于平滑阶段性流动性波动，同时提升股东结构的稳定性与质量。从资金属性看，长线资本的进入往往意味着对公司中长期成长路径与价值兑现能力的认可，为后续估值修复奠定更加坚实的资金基础。从资本市场运行规律来看，当企业战略转型逐步进入成果兑现阶段时，股东结构的优化与再平衡往往同步发生。本轮结构调整所释放的核心信号在于，国际资金正以更为积极的姿态参与公司成长进程，认可其由传统资产管理平台向"硬科技产业生态构建者"升级的战略方向。这种资本与产业逻辑的共振，有助于强化市场对公司长期价值的认知与定价信心。外资机构的逆势买入，其逻辑支撑源于首程控股基本面的深刻蜕变。公司正从传统的资产管理平台，成功向"产业生态构建者"转型。通过独特的"资本+场景+运营"三维模式，首程控股已构建起闭环生态，特别是在机器人赛道的前瞻性布局，已使其成为港股硬科技投资的标杆。2026年被市场普遍视为具身智能与人形机器人商业化加速落地的重要时间窗口。首程控股前期在机器人赛道的系统性布局，正在进入集中收获期，机器人赛道整体投资回报表现亮眼：核心项目实现高溢价： 依托对自变量科技、宇树科技等领军企业的早期重仓已实现显著账面增值，随着宇树科技等明星项目正式开启IPO冲刺，首程控股持有的股权将迎来从"账面浮盈"向"现金分红"的实质性跨越，持续增厚上市公司利润。此外，值得关注的是，在2026年马年央视春晚舞台上，宇树科技、银河通用、松延动力等机器人企业集体亮相，展示了具身智能技术在复杂动作控制与人机交互方面的突破。这不仅强化了公众认知，也标志着相关企业已进入规模化应用前夜。作为上述企业的重要早期布局方，首程控股间接受益于产业热度与商业化进程提速带来的估值重估。市场分析人士表示，今日的市场交易将促使公司股东结构更趋多元化。国际长线资金的进入，一方面提升了股票的全球流动性基础与治理透明度预期，另一方面也为未来产业扩张提供更广泛的资源协同空间。从市场经验看，当企业基本面处于上行周期且结构性不确定性逐步消除时，股东结构的优化往往成为估值修复的重要触发因素。分析人士指出，本轮筹码调整本质上是资本结构的战略再平衡，为公司进入价值兑现周期扫清短期供给压力。综合来看，首程控股当前处于三重拐点叠加阶段，首先是产业拐点—具身智能与机器人商业化加速；其次是资本拐点—投资项目进入集中兑现期；再次是结构拐点—国际长线资本入场优化股东结构。在国际资金认可与产业价值红利共振之下，公司估值逻辑正从"传统资管估值框架"向"硬科技产业平台估值框架"切换。随着产业落地与资本回报逐步兑现，市场对于首程控股作为"智能时代产业基础设施构建者"的认知将进一步强化，其长期价值重塑进程或已进入实质性阶段。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月25日 - (亚太商讯 via SeaPRwire.com) - 2月23日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK））宣布，已正式获得香港证券及期货事务监察委员会（SFC）批准，自2026年2月12日起可在其两家持牌机构（国泰君安证券（香港）有限公司及国泰君安外汇有限公司）采用国际掉期与衍生工具协会ISDA标准初始保证金模型（Standard Initial Margin Model, "SIMM" ）计算场外衍生品交易的初始保证金。ISDA SIMM 是业界通用的标准方法论，专门用于计算非集中清算衍生品的监管初始保证金。该模型通过建立统一的计算标准，使所有市场参与者得以遵循同一框架进行保证金核算，不仅避免了各机构独立开发模型所产生的额外成本，还有效减少了因算法差异引发的潜在争议。其配套的治理框架进一步确立了行业共同实践，确保保证金计提既符合全球监管要求，又充分保障了保证金的充足性。此次获批标志着国泰君安国际场外衍生品业务的风险管理能力迈上新台阶，在巩固合规与风控标杆的同时，显著提升中资券商国际化竞争力。通过采用国际市场通行的SIMM模型，公司得以接轨国际大行标准，能够更精准、高效地管理初始保证金，在有效控制交易对手风险的同时，显著节省交易成本，实现更高资本效率，增强与全球机构对手方的合作信任，从而提升业务的长期竞争力。此次获批不仅是对公司衍生品业务技术实力的认可，更是监管机构对公司内部控制、尤其是风险管理能力的又一里程碑式肯定。展望未来，国泰君安国际将进一步精进衍生品业务的内控管理体系，筑牢长远稳定发展的根基。同时，作为香港资本市场的重要一员，公司将一如既往地配合监管机构，深度参与市场基础设施建设，助力提升香港场外衍生工具市场的国际竞争力与活力。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"A"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

深圳, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 康哲药业控股有限公司 （"康哲药业"）欣然宣布，旗下德镁医药有限公司（"德镁医药"，专业聚焦皮肤健康的创新型医药企业，正申请于香港联合交易所有限公司主板独立上市，详见康哲药业日期为2025年4月22日发布的公告）已于2026年2月24日获得中国国家药品监督管理局（NMPA）受理磷酸芦可替尼乳膏（"产品"）轻中度特应性皮炎（"AD"）的新药上市许可申请（NDA）。产品拟用于其他外用药控制不佳或不建议使用时，非免疫功能受损的2岁及以上儿童和成人轻中度特应性皮炎的局部短期和非持续性慢性治疗。且该项NDA因"符合儿童生理特征的儿童用药品新品种、剂型和规格"，已获得NMPA药品审评中心批准纳入优先审评品种名单，有望加快产品AD适应症上市审评进程。特应性皮炎III期临床数据亮眼，优先审评加速上市磷酸芦可替尼乳膏已于2026年1月获得NMPA批准上市，成为中国批准的首款且唯一用于白癜风治疗的靶向药。此次增加AD适应症NDA获受理，是产品向多治疗领域拓展的关键里程碑。磷酸芦可替尼乳膏已在轻中度AD的一项随机、双盲、安慰剂对照中国三期药物临床研究取得积极结果：- 疗效优异：产品成功达到主要终点，即使用产品治疗8周，达到研究者整体评估（IGA）评分为0或1分，且较基线改善≥2分的受试者比例，显著高于安慰剂（63.0% vs 9.2%，P

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月24日，康希诺生物（688185.SH/06185.HK）宣布，公司自主研发的ACYW135群脑膜炎球菌多糖结合疫苗（CRM197载体）——曼海欣(R)扩大适用人群的补充申请已正式获得国家药品监督管理局批准。此次获批后，曼海欣(R)适用于3月龄至6周岁（83月龄）的婴幼儿及儿童，用于预防由A、C、Y、W135群脑膜炎奈瑟菌引起的流行性脑脊髓膜炎（以下简称"流脑"）。此次曼海欣(R)扩龄获批，具有重要的公共卫生和商业发展意义。一方面，在我国现行免疫规划程序中，6岁是入学前流脑疫苗接种"最后一针"的重要节点，长期以来，国内针对3岁以上儿童的多价流脑结合疫苗选择相对有限。曼海欣(R)此次扩龄获批，为学龄期儿童提供了四价流脑多糖结合疫苗接种选择，有助于填补儿童流脑防控在关键年龄阶段的保护空白，进一步完善我国流脑免疫屏障。另一方面，适用人群范围的扩大，将有助于曼海欣(R)进一步释放产品潜力，提升商业化空间，并为该产品在国际市场的推广与布局奠定更为坚实的基础。值得一提的是，康希诺生物日前已发布2025年度业绩预告，全年营收预计10.4–10.8亿元，同比增长22.88%-27.61%；归母净利润预计2450万–2900万元，将实现扭亏为盈。同时，公告明确指出，"公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海欣(R)收入保持持续增长"。这也意味着康希诺生物已进入创新疫苗商业化收获期。依托独家技术平台、领先优势及加速的国际化布局，曼海欣(R)扩龄不仅巩固了市场竞争力，也为康希诺生物的可持续增长注入新的动力。随着产品覆盖和国际拓展的推进，公司长期价值将开启更广阔的发展空间。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年新版《道路机动车辆生产企业准入审查要求》中，仿真验证能力被作为强制性关键要素写入准入审查要求，国产仿真平台迎来巨大的市场利好，进一步推动了智驾产业链加速向"自主可控"迈进。在此背景下，五一视界宣布旗下51Sim下一代智驾仿真平台 SimOne 4.0 已于近日成功完成在摩尔线程旗舰级AI训推一体全功能GPU MTT S5000上的系统性适配与深度优化。从大模型感知挖掘、4DGS模型训练到4DGS仿真推理和合成数据生成，双方强强联手，实现了国产算力与端到端智能驾驶仿真体系的完整打通，正式开启了物理AI智驾领域高置信度闭环仿真与合成数据的全栈国产化新篇章,为应对新规下的严苛验证需求提供了坚实的国产底座。算力底座的"跨代式"追赶随着端到端智驾收敛到VLA和世界模型两条路线，基于海量Log数据的高置信度闭环仿真和合成数据已成为提升算法长尾场景处理能力的关键命题。仿真效率的上限，往往取决于基础一硬件的规格。在很长一段时间里，高端GPU市场几乎被海外巨头垄断，但五一视界与摩尔线程的最新合作成果显示，这一格局正在发生微妙的变化。SimOne 4.0已完成与摩尔线程MTT S5000的深度适配。MTT S5000是专为大模型训练、推理及高性能计算而设计的全功能GPU智算卡，基于第四代MUSA架构"平湖"打造。其单卡AI算力（稠密）最高可达1000 TFLOPS，配备80GB显存，显存带宽达到1.6TB/s，卡间互联带宽为784GB/s，完整支持从FP8到FP64的全精度计算。基于SimOne 4.0实现7个周视摄像头4DGS场景重建效果在实测数据中，MTT S5000展现出了足以抗衡甚至部分超越国际主流竞品的硬实力。数据显示，MTT S5000在FP32、FP16及INT8等关键精度上实现了约1.47倍的性能增长，FP64双精度算力领先幅度约1.48倍。更值得关注的是其搭载的MTLink技术，使得卡间带宽提升约30%。MTT S5000凭借FP8提升训推效率、FP64保障计算精准、光线追踪实现高保真渲染，以自主可控的强劲底层算力，为智能驾驶提供安全、高效、可靠的核心国产算力支撑。场景实测：在复杂博弈中验证"真功夫"硬件参数的领先，最终需要在真实的算法场景中落地。在SimOne 4.0的大模型感知挖掘功能中，双方针对Qwen3-VL多模态大模型进行了深度调优。实测结果令人惊喜：无论是在8B模型还是更复杂的30B MoE架构下，MTT S5000在"预填充（Prefill）"阶段的首字响应速度（TTFT）均优于国际主流竞品，优势最高扩大至14%，且在10并发的高压环境下依然保持了稳健的吞吐量。而在更考验训练和推理能力的4DGS（4D高斯泼溅）领域，基于51Sim入选AAAI 2026的LidarPainter技术，国产算力同样经受住了考验。目前测试数据显示，在训练端，MTT S5000展现出比肩国际主流竞品的强劲性能，仅需2.5小时即可完成一个真实Clip场景的高质量重建；在推理端，面对单Clip包含1600万个高斯点的超大模型负载，MTT S5000成功实现了11路摄像头加1路激光雷达的实时闭环仿真，呈现出像素级的高保真效果。这证明了国产显卡在处理复杂光影与动态物体还原时，已经具备了生产力级别的属性,能够胜任准入审查中要求的极端工况与边界条件验证。这种高保真物理场景的重建能力，同样可迁移至具身智能机器人的空间感知与操作训练中。基于LidarPainter 技术生成高真实度新视角图像隐形护城河：构建"芯片+系统"的通用底座如果说高性能GPU的适配是攻克了"最难的骨头"，那么对国产基础软硬件生态的全面覆盖，则是五一视界构筑的一条安全护城河,也是响应国家信创战略、满足敏感行业准入要求的关键。除了图形计算领域，五一视界已悄然完成了对主流国产芯片架构的全线互认。在CPU层面，无论是基于ARM架构的华为鲲鹏、飞腾，还是基于x86架构的海光、兆芯，五一视界旗下的51Aes、51Sim等核心产品均已实现流畅部署。特别是通过华为鲲鹏技术认证并加入"鲲鹏展翅"计划，进一步夯实了其在国产服务器端的运行稳定性。在操作系统层面，为了彻底摆脱对非国产发行版的依赖，五一视界将适配工作下沉至系统内核，先后完成了与麒麟软件（银河麒麟高级服务器操作系统）及统信软件（UOS）的适配认证。这一举措意味着，对于政府、能源等有着严苛信创要求的敏感行业客户而言，他们可以选择从芯片到底层操作系统到上层应用全链路自主可控的数字孪生解决方案,从容应对日益严格的合规性审查,构建起一个不仅服务于智能驾驶，更能广泛赋能于人形机器人等具身智能终端的国产化通用基础设施。中国科技企业"国产自主可控"已经崛起从携手摩尔线程在高端算力上撕开缺口，到打通华为鲲鹏、麒麟等操作系统的生态脉络，再到积极响应新版准入审查要求提供合规的仿真验证能力，五一视界的这一系列动作表明，中国企业的"国产自主可控"正在发生量变和质变，正在缓缓崛起。这不再是简单的参数对标，而是产业生态的战略闭环。SimOne 4.0的表现证明，国产软硬件方案已经迈过了"能用"的门槛，正式进入了高精度、高负载任务的"好用"阶段。随着算法与算力的深度融合，以及政策法规对仿真验证能力的强制加持，一个繁荣的、自主可控的物理AI生态底座正在逐步成型，为中国智能驾驶产业的独立发展保驾护航,也为具身智能机器人等新兴领域的国产化落地铺平了道路。基于SimOne 4.0 的4DGS闭环仿真 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) – During the Year of the Horse Spring Festival, momentum in the "Hard Tech" sector continued to surge, with the humanoid robotics industry becoming a market focal point following its stellar performance on the Spring Festival Gala stage. Shoucheng Holdings (0697.HK) has emerged as a core target for post-holiday capital market positioning due to a series of heavy-hitting moves. These include the operational launch of the Taozhu New Creation Hub - a comprehensive robotics technology experience, sales, maintenance, and service center—followed by the dual boost of Spring Festival Gala exposure and New Year's Eve livestreaming conversions. Coupled with the positive signal of continuous recent share buybacks, the company’s solid industrial layout and clear earnings growth are expected to trigger a formal valuation recovery.By establishing a closed-loop of "Offline Landing + Strategic Investment + Traffic Conversion + Buyback Support," Shoucheng Holdings has not only demonstrated its deep layout in the robotics track but has also provided the capital market with a high-certainty investment logic through concrete industrial actions and capital behavior. The window for valuation recovery has officially opened.I. Grand Opening of the Offline Complex: Solidifying the Foundation for MonetizationAs the traffic dividends from the Spring Festival Gala and livestreaming were released, Shoucheng Holdings officially launched Taozhu New Creation Hub, its flagship robotics technology retail brand. This complex captures the core of the offline smart consumption track and injects deterministic growth into Shoucheng’s performance. It serves as a solid physical carrier to convert gala traffic and livestreaming orders, marking a new stage in Shoucheng’s full-chain service layout for offline robotics commercial scenarios.Integrated Ecosystem: The Hub constructs an "Experience + Sales + After-sales + Investment" full-model ecosystem."Store-Factory" Innovation: Utilizing an innovative "front-store, back-factory" layout, it includes a robotics maintenance and repair workshop created in collaboration with Accelerated Evolution to provide one-stop services.Market Validation: With an exhibition area exceeding 400 square meters, the Hub serves as a core scenario for investee companies to implement technology and validate market demand.Strategic Store Matrix:Wangfujing APM Store: Located in a premier trendy commercial district, focusing on "Trend Tech + First-Store Economy," targeting consumers aged 18–35.Capital Airport T2 Store: Situated in a core transportation hub with 35 million annual passengers, targeting the "40-minute pre-boarding decision" window with portable and practical smart products.This layout is a key execution of Shoucheng’s "Capital + Scenario + Ecosystem" strategy. By capturing consumer demand through digital means, it provides investee companies with valuable data for product iteration, forming a virtuous cycle of "Industry + Consumption + Maintenance".II. Dominance of the Gala Trio: National-Level Endorsement of Ecosystem StrengthThe Year of the Horse Spring Festival Gala featured a humanoid robot cluster performance as its most high-tech highlight. Among the four core robotics companies featured, three - Unitree Robotics, NOETIX Robotics, and Galbot - are Shoucheng Holdings' portfolio companies. This dominant presence provides national-level brand endorsement for the offline scenarios.The three portfolio companies demonstrated world-class capabilities across core tracks:Unitree Robotics: Deployed a 16-robot formation in the program "Wu BOT," performing high-difficulty martial arts. It achieved world-firsts in continuous parkour flips and rapid maneuvers (up to 4m/s) using self-developed dexterous hands.NOETIX Robotics: Earned the title of "Exclusive Bionic Humanoid Robot Partner" for the gala. Its "Xiaowantong N2" and "Xiaobumi" consumer products displayed lifelike facial expressions and synchronized breathing movements, signaling the acceleration of robots entering the home.Galbot: Debuted as the "Designated Embodied AI Model Robot". Its robot, "Xiao Gai," autonomously performed real-time tasks—such as picking up glass shards and folding clothes—driven by its "AstraBrain" Embodied AI model.This collective appearance is a result of Shoucheng's long-term deep layout, building a complete investment matrix across core components, whole units, and "intelligent brains".III. New Year's Eve Live-streaming: Immediate Traffic MonetizationOn the night of the Gala, Shoucheng Holdings launched the "PoBiren (Barrier-Breaker) Initiative" Live-streaming event, becoming the only industrial investor in the sector to achieve immediate traffic conversion. This successfully closed the loop of "Offline Landing - Stage Exposure - Online Traffic - Order Conversion".Solving Pain Points: The livestream addressed the "unreachable" nature of online consumption through product demonstrations and professional technical interpretations.Seamless Integration: It linked online orders to the Taozhu New Creation Hub for offline delivery and maintenance.Professional Branding: By sharing industry trends from an investor's perspective, Shoucheng deepened consumer trust and solidified its leadership in hard tech investment.ConclusionShoucheng Holdings has achieved a triple breakthrough in national exposure, immediate traffic conversion, and offline operations. Under the resonance of these multiple benefits and continued buybacks, the logic for both valuation and performance enhancement is further strengthened, allowing Shoucheng to lead the hard tech investment track and provide long-term stable returns to investors. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月22日, 纳斯达克上市公司迦里仕人才集团有限公司（Galaxy Payroll Group Limited，NASDAQ: GLXG，以下简称“迦里仕人才”）宣布，已与耐吉中国控股香港有限公司澳门分公司（NIKE China Holding HK Limited (Macau Branch)，以下简称“耐吉澳门分公司”）正式续签为期五年的战略合作协议。合作再延五年，服务范围全面覆盖核心HR职能根据协议，双方合作期限自2025年12月1日起至2030年11月30日止。在此期间，迦里仕人才将继续为耐吉澳门分公司提供涵盖本地薪资发放、考勤与休假管理、社保及税务合规申报，以及劳动法规与用工政策咨询在内的一站式人力资源外包服务。该合作模式有效支持耐吉澳门分公司聚焦其核心零售与品牌运营，提升整体组织效能。战略续约彰显客户高度信任，强化收入稳定性此次续约不仅是双方合作关系迈入新阶段的重要标志，更体现了国际头部品牌对迦里仕人才专业能力、合规水平及长期服务交付质量的高度认可。中长期合约的签署显著增强了公司未来五年收入的可预测性与现金流稳定性，进一步契合其打造高质量、抗周期业务模型的资本市场战略。本地化能力构筑核心壁垒，服务体系持续进化自2013年成立以来，迦里仕人才始终深耕港澳市场，并逐步拓展跨区域服务能力。公司凭借对香港及澳门劳动法、税务及社保政策的深度掌握，建立起扎实的本地合规能力；同时依托标准化流程与定制化方案相结合的服务体系，确保交付的一致性与可扩展性。其自主开发的薪资与考勤管理平台，在提升运营效率的同时有效保障数据安全与业务连续性，成为吸引并维系跨国企业客户的关键优势。在过往合作中，迦里仕人才已多次协助耐吉澳门分公司应对复杂用工环境下的合规挑战，其解决方案在准确性、响应速度及风险控制方面均获得充分验证，为本次长期续约奠定了坚实基础。展望未来：从服务交付迈向价值共创展望新合作周期，迦里仕人才将在现有服务框架基础上，持续优化薪资管理流程与智能考勤系统，并通过数据整合与定期管理报表，助力客户推进人力资源管理的规范化与数字化转型。双方亦约定保留通过补充协议灵活拓展服务范围的机制，确保合作节奏与客户业务发展动态同步。此次五年期战略合作的续签，不仅是对迦里仕人才专业价值的长期肯定，更是对其商业模式可持续性的有力印证。它将进一步巩固公司在港澳及亚太人力资源外包市场的品牌影响力，并为服务更多跨国零售、体育及消费品牌提供可复制的标杆案例。在全球企业日益重视合规效率、成本优化与组织韧性的背景下，迦里仕人才正凭借其深厚的本地化经验、稳健的服务体系与高粘性的优质客户基础，稳步构建长期增长动能。公司管理层表示：“我们将继续以服务能力为核心驱动力，深化与现有优质客户的战略合作，同时积极拓展更多具有长期价值的跨国及区域性企业客户，持续为股东创造稳健、可持续的回报。” Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2月23日，由上海实业（集团）有限公司（以下简称"上实集团"）与国泰海通证券股份有限公司（以下简称"国泰海通"）联合发起设立的沪港新兴产业基石基金（以下简称"基石基金"）正式启航，进入实质投资阶段。作为全国首支、上海市级市场化运作的证券类港股基石基金，基金目标总规模30亿港元，首期规模10亿港元，将聚焦集成电路、生物医药、人工智能上海三大先导产业，专项支持优质企业赴港上市，深化沪港金融与产业协同。服务上海战略，强化沪港联动上海市政府和上海市国资委指导设立的基石基金，是上海国资服务上海科技创新中心建设、推动重点产业高质量发展的重要举措，将紧密围绕上海前瞻的集成电路、生物医药、人工智能三大先导产业进行战略布局，通过资本市场赋能，加速本地创新企业国际化进程。同时，基金也将充分发挥香港作为国际金融中心的枢纽功能，构建"上海产业+香港资本"的高效联通机制，促进两地金融资源互补与市场互联，打造沪港合作新标杆。创新"双管理人"架构，汇聚两地专业力量基石基金在治理模式上采用创新的"双管理人"架构，由上实集团在港金融投资业务平台上实资本（香港）投资管理有限公司，和国泰海通在港资产管理平台海通国际资产管理有限公司共同担任基金管理人，并由沪港两地协同运营。这一合作架构充分融合了上实集团作为上海在港窗口企业的产业资源与香港本地的运营优势，及国泰海通在全球资本市场和跨境资产管理方面的专业能力，实现"产业+金融"、"上海+香港"的双重优势互补。通过建立完善的投资决策机制与风险控制体系，该架构既确保了基金运作符合国际标准，又保持了与本土产业生态的深度链接，为基金的长期稳健运作奠定了坚实基础。多元化投资策略，专注长期价值基石基金坚持市场化、专业化、国际化运作原则，以产业、金融双重视角，构建覆盖企业全生命周期的投资与赋能体系。通过灵活的多元化策略组合与深度投后服务，系统性支持上海三大先导产业优质企业的业务发展与价值实现。基石基金在重点参与上海三大先导产业优质企业赴港IPO的基石投资之外，还可以参与港股IPO锚定和已上市港股的配售投资，通过无锁定期策略保持基金的流动性，以保证基金投资收益；在市场大幅下跌时，也可通过二级市场方式，增持价值低估的优质公司股票；同时跟进优秀企业再融资及并购重组，助力可持续发展。基石基金将严格遵循"好赛道、好公司、好价格"的遴选标准，重点投向具备核心技术、高成长性和稳健现金流的行业领军企业。强化上海国资在港功能，构建跨境投资新平台基石基金是上实集团和国泰海通强化在港服务功能、完善跨境投资布局的关键举措之一。基石基金不仅进一步完善上海国资基金矩阵，填补国资基金在港股IPO及二级市场策略的空白，服务上海企业赴港上市"最后一公里"融资需求，助力构建"早期投资—成长期融资—公开市场上市"的完整产业投资生态；更通过上实集团和国泰海通的深度合作，强强联手、协作共赢，系统提升跨境合规、资产配置与复杂交易设计能力，进一步增强上海国资服务上海乃至国家战略的综合实力。展望：链接国际资本，赋能创新未来在全球科技创新竞争日益激烈的背景下，沪港新兴产业基石基金的实质启动，标志着上海在对接国际资本市场、服务本土创新方面迈出系统性的一步。在人民币国际化和"惠港五条"等政策红利支持下，基石基金将成为连接内地产业资本与国际金融资源的重要纽带。未来，基石基金将积极把握人民币国际化与金融市场双向开放机遇，持续促进国际资本投资上海核心产业，为上海三大先导产业企业提供全方位的资本服务，助力更多硬科技企业走向世界，为沪港融合与高质量发展贡献力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月24日 - (亚太商讯 via SeaPRwire.com) - 2026年2月2日，维昇药业于上海举办维臻高(R)（注射用隆培生长激素）获批上市投资者交流会。 该产品已于1月26日获得国家药品监督管理局批准上市。公司在会上表示，维臻高(R)被定位为具备里程碑意义的创新产品 - 不仅是首个在欧美获批用于儿童的长效生长激素，也是目前临床研究中唯一被证实在疗效上优于日制剂的长效生长激素产品。在生长激素赛道中，随着多款产品陆续纳入医保、价格体系快速下探，市场竞争格局正在发生变化。维昇药业以临床价值和技术壁垒为核心，打造差异化的高端产品路径。本次交流会由公司管理层系统介绍了产品研发逻辑、临床数据及当前阶段商业化策略的核心思路。本次会议邀请了多位合作伙伴与行业嘉宾出席，包括国妇婴主任医师余文教授、安科生物高级副总裁姚建平先生、副总裁鲍学科先生、上药控股副总经理宋潞潞女士、上海和睦家医院长宁院区执行院长刘晓龙先生等到场支持。同时，公司长期股东代表——碧沃投资合伙人柳丹先生亦出席交流，体现了核心股东对公司商业化路径与长期价值的持续认可。中信证券、东吴证券、天风证券和国海证券等多家大型券商及投资机构亦参与本次会议。一、产品内核：技术壁垒构建差异化护城河1.1 "暂时连接"技术的独特性在生长激素领域，由于技术壁垒高，实现长效化与保持活性分子的天然结构长期被视为"鱼与熊掌不可兼得"，而维臻高(R)的研发上市成功突破这一行业技术壁垒，是全球首款实现"长效化+天然结构"作用机理的长效生长激素。维昇药业首席商务官陈军在会上详细拆解了TransCon技术平台的突破：通过惰性载体（PEG）将天然结构的重组人生长激素暂时包裹和保护起来形成前药，前药在注射至皮下时没有活性，进入血液循环在，将惰性载体与生长激素暂时连接起来的TransCon连接结构在体温与生理pH值下发生自动裂解，7天内以特定的速率逐步释放出与人体自身分泌完全一致的2.2万道尔顿（22kD）、191个氨基酸的天然结构的生长激素。这一"暂时连接"机制与市面上其他长效生长激素的"永久连接"形成本质区别。陈军指出，目前已上市的其他长效生长激素均属于"生长激素类似物"——其活性分子结构已改变，分子量高达6万-9万道尔顿，远远高于天然生长激素的2.2万道尔顿。维臻高(R)进入人体内释放的活性分子与内源性生长激素的分子量、分子结构、组织分布以及药理特性相同，也是首款活性分子是"长效生长激素"而非"生长激素类似物"的长效产品。国妇婴主任医师余文教授从临床角度补充了关键细节：分子量过大的药物难以穿透致密的骨骺板，无法发挥生长激素的直接作用，也就可能直接影响疗效。维臻高(R)以内源性生长激素的"原药形式"发挥作用，是其头对头研究取得优效结果的理论依据和科学基础。1.2 说明书上的"法律证据"余文教授在交流中特别强调，在临床实践中，尤其是一款新药，经国家药监部门审评并写入药品说明书的内容，是判断药品疗效与安全性的核心法定依据，也是临床用药的权威规范标准，它构成了疗效与安全性判断的核心标准,是药品的"身份证"。维臻高(R)本次获批的产品说明书直接显示了其疗效优于每日制剂：境外临床研究结果："主要疗效终点是第52周时年化生长速率（AHV）。本品治疗52周时的AHV非劣效并优效于健豪宁(R)组。此外，本品治疗后的身高SDS较基线的增加幅度高于健豪宁(R)组。从治疗第26周至第52周试验结束时，对于AHV和身高SDS 较基线的变化，本品组都较健豪宁(R)组更显著。"中国临床研究结果："主要疗效终点是第52周AHV。本品治疗52周的AHV为 10.66cm/年，相比诺泽(R)组的AHV 9.75cm/年，统计分析结果显示达到非劣效性以及优效性，即证明了本品治疗的52周AHV优效于诺泽(R)组，与境外3期研究结果一致。此外，本品组治疗时的身高SDS较基线的增加幅度高于诺泽(R)组，也显示了优效性。从治疗第13周至第52周试验结束时， 对于AHV和身高SDS较基线的变化，本品组都较诺泽(R)组更显著。"1.3 安全性设计的双重保障分子安全性：由于维臻高(R)的活性成分与内源性生长激素结构完全一致，避免了未知分子风险；而其他长效生长激素均为"人造分子"，长期安全性存疑（辉瑞、诺和诺德曾尝试PEG永久修饰技术研发长效生长激素，但均因安全性和疗效问题终止研发）。局部安全性：注射部位无活性，避免脂肪萎缩等不良反应。陈军特别解释：其他部分长效产品将"7天剂量一次打入一个注射部位"，注射部位存在高浓度活性成分；维臻高(R)的"包裹"技术使其在皮下无活性，只在该发挥作用时才呈现活性，降低了导致脂肪细胞溶解、皮肤凹陷的可能，这是"另一个安全性优势"。更值得关注的是其长期安全性数据：维臻高(R)全球关键3期研究治疗1年的结果显示，其不良反应发生的种类与频率均与生长激素日制剂相似；而在治疗时间最长达6年的延长期研究中，维臻高(R)也未出现与生长激素日制剂不同的、新的不良反应类型。余教授谈到，生长激素日制剂在生长激素缺乏症患儿中已有超过40年的使用经验，其安全性特已被临床医生熟知并掌握，基于明确的研究数据，维臻高(R)与日制剂一致的安全性表现，显然也为医生的应用提供了更充分的保障。1.4 储存与使用的便利性突破维臻高(R)在不含防腐剂情况下，室温（≤30℃）可储存6个月，在2-8℃条件下可存储5年，是唯一可在室温下长期存放的生长激素。余文教授强调："这是我们当时完全没有想到的效期，并且清楚的写在说明书中。"这一特性对需要携带药物出行、参加夏令营的家庭至关重要。1.5 注射体验的创新设计维臻高(R)配备电子自动注射笔，由Phillips-Medisize公司生产，2022-2023年获欧洲和美国三项工业设计大奖（PDA 药物递送创新奖、PharmaPack 给药与包装创新奖、红点工业设计奖）。其特点包括：- 单按钮开关，药物复溶与注射全自动完成- 隐形针头设计，患儿看不到针，减少心理恐惧- 配合固定剂量双腔预充笔芯，注射前无需调节剂量，同时避免浪费- 每月4支笔芯+6支针头的一体化包装二、市场策略：技术与临床优势下的差异化商业路径2.1 定价逻辑：突出产品差异化，以技术优势形成产品价值优势维昇药业首席商务官陈军表示：维臻高(R)的年治疗费将会于产品上市时最终确定，但一定会显著高于其他长效生长激素纳入医保后的价格。但这一定价并非简单的"高端溢价"，而是基于三重锚定：- 价值锚定：产品具备"天然结构+优效+室温保存"三重独特属性，维臻高(R)作为长效生长激素迭代产品，产品的独特优势赋予了其核心定价权，将填补高端市场的真空。- 国际锚定：该产品在欧美获批上市，美国年治疗费用50-60万元，维臻高(R)以其"技术优势+临床优势+欧美品质"为背书，将临床需求和价值锚点与国际接轨。- 长期健康价值锚定：生长激素治疗具有明确的时间窗口和长期获益特征。其价值并不取决于单一年度的费用比较，而在于对终身身高结局、心理健康与社会功能的长期改善。从全周期视角衡量，该治疗所带来的健康收益与成本投入之间具有清晰、可解释的价值逻辑。这一策略的风险在于支付能力，但维昇药业的判断是：生长激素市场90%以上为自费，80%以上销售发生在私立医院。2.2 渠道布局：合纵连横的"作战地图"维昇药业作为初创企业，选择了"轻资产、重合作"的扩张路径：- 推广端：与安科生物强强联手，其高级副总裁姚建平表示，公司在生长激素领域深耕27年，以学术触达95%的生长激素KOL专家。此次与维昇药业的合作，"27年经验+划时代产品"将形成前所未有的商业化布局。双方将按地域区隔运营，维昇药业自营沿海核心市场，安科生物负责其余广阔区域，实现市场的全面覆盖。- 流通端：上药控股作为进口分销平台，依托其成熟的供应链体系，提供从通关到终端的全程服务。上药控股副总经理宋潞潞指出，维臻高(R)是其经销的大分子生物药中，唯一不含防腐剂且可常温保存6个月的产品，"这两个优势在对药品商业化成功，特别是儿童用药的商业化成功方面，至关重要"。- 诊疗端：与和睦家、小苹果、卓正等高端私立医院建立深度合作，构建"筛查-诊疗-管理"的全流程闭环。上海和睦家医院长宁院区执行院长刘晓龙表示，其患者群体对"技术领先、长期安全"的产品需求明确，维臻高(R)的核心优势与该群体需求高度匹配，具备良好的临床土壤。- 流量端：患者及家庭在疾病认知与治疗决策过程中，主要通过内容社区、AI 搜索工具及合规的互联网医疗平台获取相关科普信息，逐步形成以专业性、可及性和合规性为核心的患者信息入口，让优质医疗信息精准触达目标人群。三、团队建设：用近乎苛刻的标准筛选最强执行者维昇药业销售与商业运营副总裁潘海风详细介绍了团队建设的"高强度、严标准"体系：- 招聘标准：一线商业化团队中，约20%具备硕士学历，80%为医药相关本科背景；近三分之一来自其他公司的地区经理级别，整体商业化人员结构和行业经验显著高于行业平均水平。- 考核机制：全员"日考+周考+月考"，内容涵盖产品知识、竞品知识、临床医学、疾病知识；每日考试须达90分以上，集训落地考不合格者原机遣返，以严苛的考核标准保障团队的专业能力，确保用人标准与产品价值相一致。- 提前布局：公司提前规划、前置投入，产品上市前6个月商业化团队已90%到岗，为产品上市后的快速市场推进做好了充分准备，体现出公司对商业化执行的前置投入与系统规划。四、其他Q&A环节：问题一：在目前的定价水平下，维臻高(R)的利润率表现如何？未来随着地产化推进，盈利空间如何展望？ 回答： 公司坚持"先上市、先可及"的策略，进口阶段的毛利率足够产品上市早期的推广。随着两年多后实现地产化生产，即便在当前价格水平大幅下降的情况下，毛利率仍有望达到80%以上。从进口到地产化的路径清晰，随着市场规模的持续放量，盈利能力将随规模放量持续改善。问题二：维臻高(R)在公立医院与民营医院中的销售场景如何落地？在部分长效生长激素已进入国谈的背景下，公司如何发挥差异化优势？ 回答： 公司将覆盖三类渠道：公立医院院内、公立医院处方外配及民营医院。受国谈因素影响，公立院内并非未来主战场，核心增长将来自处方外配及民营医疗体系。同时，国家层面已明确提出要有序推进医师多机构执业，鼓励医师依法开展多点执业，医生在公立医院与民营医疗机构之间的执业流动性持续提升。这一趋势为创新、差异化产品在院外及民营场景中的推广和规范使用创造了有利条件。公司将基于这一制度环境，在所有合规场景中积极布局。问题三：除维臻高(R)外，公司其他管线在未来几年的上市节奏及协同贡献如何？ 回答： 公司在内分泌领域已布局多条管线，其中针对甲状旁腺功能减退的帕罗培特立帕肽已分别于2024年年初和年底在欧盟跟美国获批；第三个品种那韦培肽这个月底迎来其 PDUFA 日期，后续产品在中国的上市节奏有望加快。多产品协同放量后，公司整体规模有望持续跃升，长期目标是打造内分泌与代谢领域具备国际竞争力的百亿级创新药企。问题四：已使用短效生长激素的患者，是否可以无缝切换至维臻高(R)？是否有相关临床证据支持？ 回答： 国际3期试验有一个关于日制剂转换为隆培生长激素的研究。研究显示，对于平均使用日制剂已有1.14年、平均剂量为0.29 mg/kg/周的患者，转为隆培生长激素0.24mg/kg/周后，仍然保持了非常良好的追赶生长的趋势。这一研究结果证明了由日制剂转为隆培促生长素每周一次治疗仍可保持非常良好的生长趋势和疗效。问题五：维臻高(R)在长期使用方面的疗效和安全性表现如何？ 回答： 在国际3期试验的延长期实验中，患者平均治疗4.3年、最长达6年，期间患者身高持续改善，部分患者最终身高SDS甚至超过父母平均身高SDS，充分体现了产品在长期治疗中的有效性、安全性及稳定性。问题六：公司目前商业化团队建设情况如何？与安科生物的合作如何推进？ 回答： 公司首年商业化团队已基本到位，团队人员以业内资深骨干为主，强调高专业度、强培训与严格考核。区域运营上，维昇负责沿海一线重点城市，安科覆盖其他区域，双方执行统一学术与培训标准，形成"强强联合"的销售体系，共同推进产品的市场落地。五、长期展望：从单一产品到平台价值维昇药业执行董事兼首席执行官卢安邦在交流结束的致辞中描绘了公司长期发展的蓝图：维臻高(R)的获批意味着TransCon技术平台继FDA和EMA后获NMPA认可，为后续产品铺平道路。在研的帕罗培特立帕肽（甲状旁腺功能减退症）2024年美欧获批后首年销售近40亿人民币，那韦培肽（软骨发育不全）针对中国1万患儿的治疗刚需。"2026-2028是公司"十年磨一剑"的决战期，"卢安邦表示，"我们要验证从临床、注册、准入到商业化的端到端能力，最终成为内分泌代谢领域的百亿级领军企业。"本文基于2026年2月2日维昇药业投资者交流会纪要整理，内容仅供信息参考，不构成投资建议。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - February 23, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company has entered into an advertising services agreement (the "Agreement") dated February 19, 2026 with AJO Capital Inc. ("AJO"), whereby AJO will provide marketing and investor awareness services to raise public awareness of GMG, including without limitation, original news articles, podcast and interview content creation, newspaper, television, radio and industry network distribution, as well as social media support (the "Services"). GMG has agreed to a monthly payment of US$26,500 for the provision by AJO of the Services. The Agreement commenced on February 19, 2026 and has an initial term of four (4) months unless earlier terminated. The Agreement may be renewed upon mutual written agreement at least thirty (30) days prior to the expiration of the initial term, subject to any modifications to compensation and payment terms as the parties may agree.AJO is a private company based in New York, United States dedicated to providing financial information and media and communication services. The Company will not issue any securities of the Company to AJO as compensation. To the Company's knowledge, AJO and its directors and officers are arm's length from the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, services to be provided by AJO, term and termination of the Agreement and compensation payable to AJO pursuant to the Agreement.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the services to be provided by AJO, covenants by AJO under the Agreement, length of the term of the Agreement, termination of the Agreement and compensation payable to AJO pursuant to the Agreement, that the Company will not issue any future securities to AJO as compensation under the Agreement, that AJO acts at arm's length to the Company and none of AJO, its directors nor officers have any direct or indirect interest in the Company and its securities nor do they have any right to acquire such interests. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, failure by AJO to render services in accordance with the Agreement, breach of the Agreement by either parties, early termination of the Agreement and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285033 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月23日 - (亚太商讯 via SeaPRwire.com) - 近日，由斯坦福大学教授、"AI教母"李飞飞创办的美国世界模型独角兽World Labs官宣完成新一轮10亿美元融资，约合人民币69.1亿元，其中知名CAD厂商Autodesk单独注资2亿美元，折合人民币13.8亿元，英伟达、AMD等科技巨头及多家投资机构同步跟投。这一重磅消息再次将空间智能、物理AI及世界模型赛道推向资本聚光灯下。在这一全球科技浪潮下，国内物理AI领域的先行者五一视界（6651.HK），其投资价值正逐步凸显。作为李飞飞深耕AI领域的核心布局，World Labs的融资热度，本质上是资本对"AI从数字符号走向物理世界"这一趋势的坚定押注。长期以来，主流AI模型多局限于文本、图像等数字领域，虽能实现精准的语义理解与生成，却无法掌握物理世界的基本规律，正如业内所言，这类AI"能言善辩却手足无措"，而世界模型的出现正是为了弥补这一短板。简单来说，世界模型就是让AI构建对三维物理世界的认知，模拟空间关系、物理规律，实现数字世界与物理世界的精准映射，而空间智能与物理AI则是其核心支撑。空间智能是世界模型的基础，核心是让AI具备感知、理解三维空间的能力，就像生物通过进化形成的生存本能，能够预判物体运动轨迹、识别空间布局；物理AI则是连接数字与物理世界的桥梁，区别于传统数字AI，它能够模拟重力、摩擦力等物理属性，实现"感知-预测-行动"的闭环，让AI从"理论家"变成"实践者"。World Labs推出的首款产品Marble，便能够依据图像或文本提示生成三维世界，正是这种技术逻辑的落地体现。借助此次新筹集到的资金，World Labs 将把重点放在提升该产品在机器人和科学发现等领域的应用能力上，进一步拓展其商业应用场景。此次Autodesk的大额投资，更揭开了世界模型的产业落地逻辑。作为建筑、工程领域的CAD软件巨头，Autodesk需要打通"设计-模拟-落地"的全流程，而World Labs的世界模型技术恰好能与其3D设计工具深度融合，自动化简化建模流程，重新定义建筑、工程等行业的创作模式。这也意味着，世界模型不再是实验室里的技术概念，已进入产业落地阶段，而空间智能与物理AI的商业化价值，正被科技巨头逐步挖掘。作为中国首家登陆资本市场的物理AI企业，五一视界凭借自主研发的51Aes（数字孪生平台）、51Sim（智驾仿真平台）、51Earth（数字地球平台）等核心产品，早已深耕空间智能、数字孪生与物理AI领域，以"克隆地球"为愿景，形成了"合成数据-空间智能模型-仿真训练平台"的全链条物理 AI 闭环生态，与World Labs的技术布局同频共振。值得注意的是，五一视界已正式纳入恒生综合指数，凭借硬科技属性与核心技术壁垒，获得了海内外资本市场的广泛认可。随着World Labs引领的世界模型赛道持续升温，物理AI作为AI下一个十年的核心增长点，市场空间将持续扩大。五一视界深耕行业多年积累的技术优势、丰富的产业落地经验与完善的业务生态，使其在国内乃至全球市场都具备显著竞争力。此次World Labs的10亿美元融资，不仅改写了AI创业公司的估值逻辑，更预示着空间智能、物理AI时代的加速到来。对于投资者而言，五一视界作为国内物理AI领域的标杆企业，其布局契合全球科技发展趋势，具备清晰的产业落地路径与长期增长潜力，无疑是把握这一科技风口的核心标的，其投资价值有望在行业爆发期中持续释放。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

圣地亚哥, 2026年2月23日 - (亚太商讯 via SeaPRwire.com) - 通用原子航空系统公司（GA-ASI）正在为其顶级机型MQ-9B天卫者®与海卫者®开发远程离场武器系统。海军和空军作战人员持续需要能够在远距离锁定目标的平台，尤其是在西太平洋广阔的海空区域。正因如此，通用原子航空系统公司（GA-ASI）的工程师们已着手改造MQ-9B的载荷、稳定性、航程等特性，以适配新一代远程精确制导武器。通用原子航空系统公司总裁戴维·亚历山大表示：“MQ-9B在实战中持续展现卓越性能，我们的全球客户名单不断扩大。通过拓展任务范围，我们致力于持续提升该机型的价值。MQ-9B具备超凡的载荷能力，因此增加远程武器携带能力以扩展任务组合是顺理成章之举。”目前GA-ASI已完成所有性能分析，确信MQ-9B具备长距离携带远程武器的能力，同时能保持持久作战效能。公司工程师团队正持续优化武器集成技术方案及作战概念设计，重点研究洛克希德·马丁公司的联合空对地远程导弹、远程反舰导弹，以及康斯伯格/雷神联合攻击导弹等武器系统。通用原子航空系统公司计划最早于2026年实现新型武器的实弹飞行测试。假设性任务场景可能如下：MQ-9B无人机可从西太平洋或南太平洋多个友军基地起飞，飞抵预定待命点并在敌方武器杀伤区外盘旋待命。若接到武器投放指令，该机可协同美军或盟军其他作战行动实施打击。除“天卫”和“海卫”型号外，MQ-9B系列还包括正在交付英国皇家空军的“护卫者RG Mk1”。通用原子航空系统公司还与比利时、加拿大、丹麦、德国、印度、日本、波兰、台湾地区以及美国空军（为特种作战司令部提供支持）签订了MQ-9B采购合同。MQ-9B还参与了美国海军多项演习，包括“北方边缘”演习、‘综合作战演习’、“环太平洋军事演习”以及“舰队航行”演习。关于通用航空系统公司通用原子航空系统公司是全球领先的无人飞行器系统（UAS）制造商。捕食者®系列无人机系统累计飞行时长逾900万小时，服役超过30年，涵盖MQ-9A死神®、MQ-1C灰鹰®、MQ-20复仇者®以及MQ-9B天卫者®/海卫者®等机型。公司致力于提供长航时、多任务解决方案，实现持续态势感知与快速打击能力。更多信息请访问https://www.ga-asi.com。复仇者、鹰眼、灰鹰、山猫、捕食者、死神、海卫士及天卫士均为通用原子航空系统公司注册商标，在美国及其他国家/地区享有法律保护。GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) is developing the addition of long-range standoff weapons to its top-of-the-line MQ-9B SkyGuardian® and SeaGuardian®.Demand continues from naval and air warfighters for platforms that can hold targets at risk from great ranges, especially over the expanses of air and water in the Western Pacific. That's why GA-ASI engineers have begun the work of adapting MQ-9B's payload, stability, range and other features to accommodate the new generation of extended-range precision weapons."MQ-9B continues to impress in the field and we keep adding to our global customer list," said GA-ASI President David R. Alexander. "We want to continue to build value in the aircraft by expanding into more missions. MQ-9B features extraordinary payload capacity, so it only makes sense to add to our mission sets with the ability to carry long-range weapons."So far, GA-ASI has performed all the performance analytics and is confident in MQ-9B's ability to carry long-range weapons over long distances, while providing a measure of persistence and endurance. Company engineers and others continue to refine the technical aspects of this integration and potential concepts of operation, eyeing weapons such as the Lockheed Martin Joint Air-to-Surface Standoff Missile andLong-Range Anti-Ship Missile, as well as the Kongsberg/Raytheon Joint Strike Missile.GA-ASI plans to fly at least one of these new weapons as early as 2026.Hypothetically, a mission profile might look like this: MQ-9Bs could launch from a number of friendly bases in the Western or Southern Pacific, fly to a hold point and loiter there outside a hostile power's weapons engagement zone. If the order came to release the weapons, the aircraft could launch them in coordination with other U.S. or allied operations.In addition to the SkyGuardian and SeaGuardian models, MQ-9B also includes the Protector RG Mk1 that is currently being delivered to the United Kingdom's Royal Air Force (RAF). GA-ASI also has MQ-9B procurement contracts with Belgium, Canada, Denmark, Germany, India, Japan, Poland, Taiwan and the U.S. Air Force in support of the Special Operations Command. MQ-9B has also been featured in various U.S. Navy exercises, including Northern Edge, Integrated Battle Problem, RIMPAC, and Group Sail.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加利福尼亚州圣地亚哥, 2026年2月23日 - (亚太商讯 via SeaPRwire.com) - 通用原子航空系统公司（GA-ASI）与美国空军合作，在南加州爱德华兹空军基地使用其MQ-20复仇者®无人喷气机及配备最新政府参考标准的F-22猛禽战斗机，完成了最新自主任务演示。(GA-ASI)在南加州爱德华兹空军基地完成最新演示任务，其MQ-20复仇者®无人喷气机与搭载最新政府参考自主软件的F-22猛禽战斗机协同执行了自主飞行。此次测试展示了F-22与MQ-20之间的有人-无人协同作战能力，通过自主系统与战术数据链实现平台间协同作。此次任务包含MQ-20与F-22之间的实机协同演练，其中MQ-20由机载人类飞行员操控，突显了其接收并执行协同指令的能力。通用原子航空系统公司总裁戴维·R·亚历山大表示："我们对此次任务借助政府先进自主系统实现的完美执行深表赞赏。本次演示突显了任务要素的集成能力，以及自主系统利用机载传感器独立决策并执行F-22战机指令的卓越性能。"此次演示展示了有人-无人协同作战能力，实现了MQ-20与F-22之间的快速软件集成，并运用了用于军事平台间通信与协调的战术数据链。MQ-20成功与F-22完成信息交换，F-22通过Autonodyne Bashi飞行员车辆接口（PVI）向MQ-20发送自主指令，引导其执行战术机动、调整航点，并完成空中巡逻（CAP）及空中威胁拦截任务。此次演示凸显了协同作战飞机（CCA）作为有人平台作战效能倍增器的潜力，实现了自主系统与人类飞行员的协同作战。通用原子航空系统公司的MQ-20复仇者无人喷气机作为CCA替代机型已服役五年有余，其作用贯穿于该公司专为该任务研发的XQ-67A和YFQ-42A机型问世前后。关于通用原子航空系统公司通用原子航空系统公司是全球领先的无人飞行器系统（UAS）制造商。捕食者®系列无人机系统累计飞行时长超过900万小时，服役逾30年，涵盖MQ-9A死神®、MQ-1C灰鹰®、MQ-20复仇者®、MQ-9B天卫者®/海卫者®、XQ-67A及YFQ-42A等机型。公司致力于提供长航时、多任务解决方案，实现持续态势感知与快速打击能力。如需了解更多信息，请访问 www.ga-asi.com。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 和 SkyGuardian 是通用原子航空系统公司（General Atomics Aeronautical Systems, Inc.）在美国及其他国家/地区注册的商标。通用原子航空系统公司媒体关系部通用原子航空系统公司 ASI-MediaRelations@ga-asi.com(858) 524-8101来源：通用原子航空系统公司 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - In collaboration with the U.S. Air Force, General Atomics Aeronautical Systems, Inc. (GA-ASI) conducted its latest demonstration performing an autonomous mission out of Edwards Air Force Base in Southern California using its MQ-20 Avenger® unmanned jet and an F-22 Raptor equipped with the latest government reference autonomy software. The test, which showcased Manned-Unmanned Teaming between the F-22 and MQ-20, leveraged autonomy and the tactical data link to enable coordination between the platforms.The mission included a live engagement between the MQ-20 and the F-22 as the command aircraft flown by an onboard human pilot, highlighting the ability to receive and execute teaming commands."We appreciate the flawless execution of this mission using the government's advanced autonomous systems," said GA-ASI President David R. Alexander. "This demo featured the integration of mission elements and the ability of autonomy to utilize onboard sensors to make independent decisions and execute commands from the F-22."The demonstration showcased Manned-Unmanned Teaming and rapid software integration between the MQ-20 and the F-22, and a tactical data link used for communication and coordination between military platforms. The MQ-20 successfully exchanged messages with the F-22, and the F-22 was able to send autonomy commands to the MQ-20 via the Autonodyne Bashi Pilot Vehicle Interface (PVI), directing the MQ-20 to execute tactical maneuvers and adjust waypoints, and perform Combat Air Patrol (CAP) and airborne threat engagement tasks.This demonstration highlighted the potential of CCAs to act as force multipliers for manned platforms, enabling collaboration between autonomous systems and human pilots. GA-ASI's MQ-20 Avenger unmanned jet has served as a surrogate CCA for more than five years, both before and since the arrival of GA-ASI's purpose-built XQ-67A and YFQ-42A aircraft.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, MQ-9B SkyGuardian®/SeaGuardian®, XQ-67A, and YFQ-42A. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SAN DIEGO, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) is giving its U.S. Air Force Collaborative Combat Aircraft a new name: YFQ-42A Dark Merlin.Dark merlins, deadly falcons known for their black feathers and devouring of other falcons as prey, often collaborate in groups for maximum effect against their targets. The Cornell Lab of Ornithology describes the merlin as a "small, fierce falcon that uses surprise attacks" to bring down its prey in flight. The dark merlin is native to the Pacific Northwest of the United States, often migrating into southern California, where bird spotters routinely report seeing them near the YFQ-42A's manufacturing home in San Diego.The 1962 book "Profiles of the Future" imagined global technological marvels yet to change the world, offering that "any sufficiently advanced technology is indistinguishable from magic." It's no coincidence that the Dark Merlin name also reflects the wizardry of Merlin from Arthurian legend, paying homage to the somewhat supernatural new era of semi-autonomous air combat."Dark merlins are hunting machines, built for speed and aerodynamics," said GA-ASI President David R. Alexander. "They harass other falcons for fun, and they eat what they kill. The name sums up our new uncrewed fighter perfectly."The U.S. Air Force official prefix "Y" denotes that the initial few aircraft are early, production-representative test models, while "F" denotes fighter and "Q" denotes uncrewed aircraft. When aircraft enter production, they drop the "Y" - for example, the YF-16 became the F-16 with the nickname "Fighting Falcon" - and GA-ASI expects its new CCA to become the FQ-42A with the nickname "Dark Merlin."The Dark Merlin has been stacking up milestones and achievements since GA-ASI was selected by the U.S. Air Force in April 2024 to build production-representative flight test articles for the CCA program. In August 2025, YFQ-42A delivered the U.S. Air Force its first successful CCA flight and followed that this month with the service's first CCA flight using mission autonomy software. Between those milestones, GA-ASI has built and flown multiple Dark Merlins, conducting push-button autonomous takeoffs and landings and other accomplishments as the test program continues.YFQ-42A Dark Merlin is a purpose-built CCA platform developed as part of GA-ASI's ongoing investment in next-generation autonomous combat aircraft. The aircraft's modular design enables rapid integration of mission systems. GA-ASI's autonomy architecture, demonstrated through multiple live flight tests, provides the foundation for human-machine teaming in complex combat scenarios.GA-ASI has been building and flying uncrewed jets for nearly two decades, beginning with the company-funded, weaponized MQ-20 Avenger® in 2008. Ongoing company investment in Avenger continues to yield results, as the aircraft routinely serves as a CCA surrogate for advanced autonomy development and testing in both government programs and company-funded research and development. The company's XQ-67A Off-Board Sensing Station jet, developed in collaboration with the U.S. Air Force Research Laboratory, offers a cutting-edge model for autonomous collaborative platforms with advanced airborne sensing and served as a flying prototype for YFQ-42A Dark Merlin.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

加利福尼亚州圣地亚哥市, 2026年2月23日 - (亚太商讯 via SeaPRwire.com) - 通用原子航空系统公司（GA-ASI）为其美国空军协作作战飞机赋予了新名称：YFQ-42A“暗影梅林”。暗色游隼是一种致命的猛禽，以黑色羽毛和捕食其他游隼为食而闻名，它们常结群行动以最大化对猎物的杀伤力。康奈尔大学鸟类学实验室将游隼描述为“体型娇小却凶猛的猛禽，擅长突袭”，能在飞行中击落猎物。暗色游隼原产于美国太平洋西北部，常迁徙至南加州地区。观鸟者常在圣地亚哥YFQ-42A战斗机制造基地附近目击其踪迹。1962年出版的《未来图景》一书曾预言尚未改变世界的全球性技术奇迹，提出“任何足够先进的技术都与魔法无异”的观点。“暗影猎鹰”之名恰如其分地呼应了亚瑟王传说中梅林的魔法，向半自主空战这一略带超自然色彩的新纪元致敬。通用原子航空系统公司总裁戴维·亚历山大表示：“暗影猎鹰是为速度与空气动力学打造的狩猎机器。它们会戏弄其他猎鹰取乐，并吞食猎物。这个名字完美概括了我们新型无人战斗机的特质。”美国空军官方前缀“Y”表示首批少量飞机是代表量产的早期测试机型，而“F”代表战斗机，“Q”代表无人飞机。当飞机进入量产阶段时，“Y”前缀将被移除——例如YF-16便更名为F-16并获得“战斗猎鹰”的绰号——而通用原子航空系统公司（GA-ASI）预计其新型CCA将定型为FQ-42A，绰号“暗影梅林”。自2024年4月GA-ASI获选为美国空军建造CCA项目量产型飞行测试样机以来，暗影梅林持续取得里程碑式进展。2025年8月，YFQ-42A完成美国空军首架CCA成功试飞，本月又实现该军种首次搭载任务自主软件的CCA飞行。在此期间，GA-ASI持续建造并试飞多架暗影梅林，在推进按钮式自主起降等测试项目中不断取得新突破。YFQ-42A“暗黑梅林”是GA-ASI持续投入下一代自主作战飞机研发的专属平台。其模块化设计可快速集成任务系统，经多次实飞验证的自主架构为复杂作战场景中的人机协同奠定基础。GA-ASI公司近二十年来持续研发无人驾驶喷气机，其里程碑始于2008年自主研发的武器化MQ-20复仇者®无人机。该公司对复仇者系列的持续投入不断取得成果，该机型现已成为政府项目及自主研发中先进自主系统开发测试的标准CCA替代平台。该公司与美国空军研究实验室联合开发的XQ-67A机载传感站喷气机，为具备先进机载传感能力的自主协同平台提供了尖端范本，并作为YFQ-42A暗影梅林的飞行原型机投入使用。关于通用航空系统公司通用原子航空系统公司是全球领先的无人飞行器系统（UAS）制造商。捕食者®系列无人机系统累计飞行时长逾900万小时，服役超过30年，涵盖MQ-9A死神®、MQ-1C灰鹰®、MQ-20复仇者®以及MQ-9B天卫者®/海卫者®等机型。公司致力于提供长航时、多任务解决方案，实现持续态势感知与快速打击能力。如需了解更多信息，请访问 https://www.ga-asi.com/。复仇者、鹰眼、灰鹰、山猫、捕食者、死神、海卫士和天卫士均为通用原子航空系统公司的商标，在美国及其他国家注册。GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BOSTON, MA, Feb 23, 2026 - (ACN Newswire via SeaPRwire.com) - Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, today announced it has initiated a research collaboration with the University of Georgia (UGA) as part of a $100M grant to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.The collaboration follows a previously announced Non-Disclosure Agreement (NDA) signed in March 2025 and formalizes the framework for evaluating Bioxytran’s novel galectin antagonist as a potential therapeutic for infected poultry . The research is being led by Dr. Daniela Rajao DVM, MS, PhD, a renowned expert in virology and poultry medicine, College of Veterinary Medicine, Department of Population Health at UGA .Bioxytran’s drug candidate, PHM23, utilizes a novel mechanism of action that targets galectin proteins critical to viral replication. By blocking viral spike proteins from attaching to host cells, the therapy aims to neutralize the virus and halt its spread . In vitro studies have already demonstrated the molecule's effectiveness against viruses similar to H5N1, providing a strong foundation for this new research ."The initiation of this research with the University of Georgia, a world leader in poultry health, marks a significant milestone for Bioxytran," said David Platt, CEO of Bioxytran, Inc. "The ongoing H5N1 outbreaks present a urgent threat to the global food supply and economy, requiring immediate mass culling that results in billions of dollars in losses. We believe our galectin antagonist technology offers a promising path forward—not just for containment, but for a humane and sustainable solution to protect animal health."The potential of this research has already garnered significant academic recognition. Following the establishment of the collaboration, UGA selected PHM23 as one of a handful of molecules to be featured in its grant submission to the U.S. Department of Agriculture’s (USDA) prestigious $100 million HPAI Poultry Innovation Grand Challenge . This inclusion underscores the scientific promise of Bioxytran’s platform in addressing one of agriculture's most pressing challenges.Current protocols for managing bird flu outbreaks often necessitate the culling of entire flocks to prevent the virus's spread. Bioxytran’s approach could offer a more effective alternative, enable rapid containment of the virus and mitigate the devastating economic impact on farmers and consumers .Bioxytran is actively seeking further partnerships with academic, industry, and government stakeholders to accelerate the development and deployment of PHM23 in response to this urgent global need .About Bioxytran, Inc. Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in virology, cancer metastasis, and oxygen transport. Its leading antiviral platform utilizes galectin antagonists to combat viral diseases. For more information, visit www.bioxytraninc.comAbout University of Georgia The University of Georgia is a land-grant and sea-grant university with a worldwide reputation for its expertise in poultry science and veterinary medicine. Its College of Veterinary Medicine and related research institutes are leaders in combating animal diseases that threaten the food supply.Investor Relations Contact: David Platt, PhD/CEO Bioxytran, Inc. 617-454-1199 david.platt@bioxytraninc.com Forward-Looking Statements This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com